Richard Matthew Moore's Insider Trades & SAST Disclosures
Richard Matthew Moore's most recent trade in Ventyx Biosciences Inc was a trade of 145,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard Matthew Moore.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ventyx Biosciences Inc | Matthew Richard Moore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Ventyx Biosciences Inc | Matthew Richard Moore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 320,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 8.74 per share. | 01 May 2024 | 4,681 | 145,505 (0%) | 0% | 8.7 | 40,902 | Common Stock |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 4,166 | 150,186 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 11.12 per share. | 04 Mar 2024 | 3,468 | 146,020 (0%) | 0% | 11.1 | 38,568 | Common Stock |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Moore Matthew Richard | SVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Richard Matthew Moore | SVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 39,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Moore Richard Matthew | SVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 35,300 | 0 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Moore Richard | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 26,666 | 81,256 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Richard Moore Matthew | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 26,666 | 107,922 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Matthew Moore Richard | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 19,750 | 145,322 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Richard Moore Matthew | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 17,650 | 125,572 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Richard Matthew Moore | SVP and Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 4,166 | 149,488 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Richard Matthew Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 126,000 | 126,000 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Richard Matthew Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 28,000 | 54,590 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 39,500 | 39,500 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 14,900 | 26,590 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | See Remarks | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 02 Mar 2023 | 1,589 | 11,711 (0%) | 0% | 15.8 | 25,134 | Common Stock |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | See Remarks | Sale of securities on an exchange or to another person at price $ 16.52 per share. | 02 Mar 2023 | 21 | 11,690 (0%) | 0% | 16.5 | 347 | Common Stock |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 35,300 | 35,300 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 13,300 | 13,300 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Matthew Richard Moore | SVP and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges